Resources for media and journalists.
26 January 2017
GENEVA – Latest results show that programs supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria have achieved significant increases in the number of people receiving treatment for HIV, diagnosis and treatment for TB and having an insecticide treated net to prevent malaria.
The new results, highlighting cumulative progress by programs supported by the Global Fund since 2002, show that the number of people currently on antiretroviral therapy increased 8.5 percent to 10 million. New smear-positive TB cases detected and treated rose by 9.4 percent to more than 16.6 million. Over 713 million insecticide treated nets were distributed to help families protect themselves from malaria, an increase of 8.1 percent. The results are based on data from the first half of 2016.
“These figures represent 15 years of impressive impact,” said Mark Dybul, the Executive Director of the Global Fund. “Global investments in programs that free communities from the burden of these diseases are achieving results that have saved more than 20 million lives.”
Additional results include: 3.8 million HIV-positive women receiving services to prevent transmission of HIV to unborn children; 334,000 people treated for multidrug-resistant TB; 626 million cases of malaria treated.
The Global Fund, which reports results twice a year, this year began implementing a strategy 2017-2022 to maximize impact, strengthen systems for health, promote and protect human rights and gender equality, and mobilize additional resources.
The Global Fund is a 21st-century partnership designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics. As a partnership between governments, civil society, the private sector and people affected by the diseases, the Global Fund mobilizes and invests nearly US$4 billion a year to support programs run by local experts in more than 100 countries. By challenging barriers and embracing innovative approaches, we are working together to better serve people affected by the diseases.
For more information, please contact:
Mobile: +41 79 916 0136